US4454117A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunization against infection by Escherichia coli
Assignee: Bactex Inc
•
Filing: 1982-09-13
•
Granted: 1984-06-12
•
Expires: 2002-09-13
Abstract
Abstract There is provided a vaccine material capable of providing substantial levels of protection against human disease caused by infection with Escherichia coli. The protecting means comprises pili of the infecting organism. The protection is given either by administering the pili directly to the subject to be protected or to a pregnant or lactating female where protection of the newborn is desired.
Inventors
- 👤 Charles C. Brinton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 02:59
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/195; C07K14/24; C07K14/245; C07K16/00; C07K16/12; C07K16/1203; C07K16/1228; C07K16/1232; A; A61; A61K; A61K38/00; A61K39/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
116 words
A method of protecting subjects susceptable thereto against colibacillosis caused by a member of a predetermined first group of strains of piliated E. coli having type 1 pili or NMS pili which comprises administering to a subject in need of protection. (a) pili derived from at least one member of a second group of strains of piliated E. coli organisms selected from the group of organisms having Type 1 pili and those having NMS pili wherein cells of organisms of said first group are agglutinable by serum containing antibodies against pili from said second group, said first group consisting of strains which may be the same as or different from the strains of said second group.
Claim 2
Independent Claim
116 words
A method of protecting subjects susceptable thereto against colibacillosis caused by a member of a predetermined first group of strains of piliated E. coli having type 1 pili or NMS pili which comprises administering to a subject in need of protection. (a) pili derived from at least one member of a second group of strains of piliated E. coli organisms selected from the group of organisms having Type 1 pili and those having NMS pili wherein cells of organisms of said first group are agglutinable by serum containing antibodies against pili from said second group, said first group consisting of strains which may be the same as or different from the strains of said second group.
Claim 3
Dependent Claim
25 words
A method of claim 1 wherein the administration is provided at least once to the subjects between about 5 and about 60 days before infection.
Claim 4
Dependent Claim
19 words
A method of claim 2 wherein there is administered between 1 and 100 μg/Kg body weight of the pili.
Claim 5
Dependent Claim
30 words
A method of claim 3 wherein the pili are derived from Type 1 pili or NMS pili of E. coli H 10407 (ATCC 31705) or E. coli E-25 (ATCC 31703).
Claim 6
Dependent Claim
121 words
A vaccine composition capable of raising the antibody level of a subject susceptable to Coli bacillosis to a level sufficient to provide protection against infection caused by a member of a first group of strains of piliated E. coli comprising: (a) pili derived from at least one member of a second group of strains of piliated E. coli organisms selected from the group of organisms having Type 1 pili and those having NMS pili wherein cells of organisms of said first group are agglutinable by serum containing antibodies against pili from said second group, said first group consisting of strains which may be the same as or different from the strains of said second group, and a pharmaceutically acceptable vaccine carrier.
Claim 7
Dependent Claim
121 words
A vaccine composition capable of raising the antibody level of a subject susceptable to Coli bacillosis to a level sufficient to provide protection against infection caused by a member of a first group of strains of piliated E. coli comprising: (a) pili derived from at least one member of a second group of strains of piliated E. coli organisms selected from the group of organisms having Type 1 pili and those having NMS pili wherein cells of organisms of said first group are agglutinable by serum containing antibodies against pili from said second group, said first group consisting of strains which may be the same as or different from the strains of said second group, and a pharmaceutically acceptable vaccine carrier.
Claim 8
Dependent Claim
53 words
A vaccine composition of claim 5 comprising pili derived from more than one member of the second group of strains wherein each of said members of said second group are capable of producing antibodies which will cause the cells of at least one member of said first group to agglutinate in their presence.
Claim 9
Dependent Claim
24 words
A vaccine composition of claim 6 wherein a strain of the second group is E. coli H 10407 (ATCC 31705) or E-25 (ATCC 31703).
Claim 10
Dependent Claim
21 words
A vaccine composition of claim 7 comprising 1-30 mg of pili of the second group per 10 ml of injectable vehicle.
Claim 11
Dependent Claim
13 words
A vaccine composition of claim 8 wherein the vehicle is physiologically acceptable saline.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-12 | 1987-12-12 | 1988-06-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-12 | 1991-12-12 | 1992-06-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-12 | 1995-12-12 | 1996-06-12 | $7700.00 | Window Closed / Lapsed |